Ritamum pharma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 604,782 | 726,532 | 692,312 | 1,108,070 | 1,431,894 | 1,140,177 | 1,168,280 | 1,219,650 |
| Profit before tax | - | - | 139,092 | 347,484 | 597,242 | 366,068 | 444,618 | 446,467 |
| Net profit | 116,792 | 201,798 | 117,686 | 302,233 | 507,317 | 310,559 | 376,364 | 375,020 |
| Equity | 123,681 | 261,949 | 349,046 | 421,546 | 471,216 | 466,950 | 566,844 | 603,040 |
| Liabilities | 59,338 | 109,495 | 27,763 | 99,793 | 139,398 | 115,426 | 114,884 | 185,286 |
| Non-current assets | 11,175 | 19,271 | 15,710 | 11,537 | 12,002 | 17,860 | 13,134 | 102,077 |
| Current assets | 171,844 | 352,173 | 360,970 | 509,579 | 598,273 | 563,985 | 667,934 | 684,183 |
| Total assets | 183,019 | 371,444 | 376,680 | 521,116 | 610,275 | 581,845 | 681,068 | 786,260 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 374,985 | 306,164 | 331,888 |
| Social insurance contributions | - | - | - | - | - | 20,435 | 22,896 | 24,012 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +292.2% | +20.1% | -4.7% | +60.1% | +29.2% | -20.4% | +2.5% | +4.4% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 63.8% | 54.3% | 31.2% | 58.0% | 83.1% | 53.4% | 55.3% | 47.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 94.4% | 77.0% | 33.7% | 71.7% | 107.7% | 66.5% | 66.4% | 62.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 19.3% | 27.8% | 17.0% | 27.3% | 35.4% | 27.2% | 32.2% | 30.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | 20.1% | 31.4% | 41.7% | 32.1% | 38.1% | 36.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.5 | 0.4 | 0.1 | 0.2 | 0.3 | 0.2 | 0.2 | 0.3 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 78,036 | 136,226 | 180,605 | 225,369 | 286,379 | 228,035 | 233,656 | 252,343 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Ritamum pharma - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-01-16 | 2025-01-20 | 74.41 |
| 2023-04-18 | 2023-04-19 | 121.01 |
Ritamum pharma - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-05-14 | 2026-05-14 | 1415.57 |
| 2025-11-28 | 2025-12-12 | 1.0 |
| 2024-12-30 | 2025-01-15 | 1.0 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Ritamum pharma, UAB (code 304451021) is a Private Limited Liability Company engaged in the manufacture of other food products n.e.c. In 2025, the company generated €1.22M in revenue and €375.0K in net profit, corresponding to a 30.7% profit margin. Revenue increased by 4.4% year on year and by 7.0% over two years, showing a steady upward trend from €1.14M in 2023 to €1.17M in 2024 and €1.22M in 2025. Net profit also remained strong, rising from €310.6K in 2023 to €376.4K in 2024 before settling at €375.0K in 2025. The balance sheet expanded to €786.3K in total assets, supported by €603.0K in equity and €185.3K in liabilities. The equity ratio stood at 76.7%, with debt-to-equity at 0.31. Asset turnover was 1.55x, while ROE reached 62.2% and ROA 47.7%. Revenue per employee was €304.9K and profit per employee €93.8K, indicating solid productivity.